EUVIMEDEUVIMED entdecken
Crossref

FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder

Mayank Gupta, Nihit Gupta

Advances in Neurodevelopmental Disorders · 2023-06 · 7 (2) · 300-306

DOI: 10.1007/s41252-022-00301-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Neurodevelopmental Disorders, online erschienen am 26.10.2022. Verfasst von Mayank Gupta und 1 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gupta, M., & Gupta, N. (2023). FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder. Advances in Neurodevelopmental Disorders, 7(2), 300-306. https://doi.org/10.1007/s41252-022-00301-6

Vancouver

Gupta M, Gupta N. FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder. Advances in Neurodevelopmental Disorders. 2023;7(2):300-306. doi:10.1007/s41252-022-00301-6

BibTeX
@article{Gupta2023,
  author = {Gupta, Mayank and Gupta, Nihit},
  title = {FDA Black Box Warning for SSRI: Reexamining the Role of High-Functioning Autism as a Confounder},
  journal = {Advances in Neurodevelopmental Disorders},
  year = {2023},
  volume = {7},
  number = {2},
  pages = {300--306},
  doi = {10.1007/s41252-022-00301-6}
}
Kostenlos starten →